AI Governance in Healthcare Facilities: FDA QMSR, CMS Oversight, and the Patient Safety Accountability Framework

THE DIRECT ANSWER

FDA's Quality Management System Regulation (QMSR) has been enforceable since February 2, 2026, aligning U.S. device quality rules with ISO 13485:2016 for manufacturers of AI/ML medical devices. CMS still governs hospital AI through existing Conditions of Participation—not a separate AI CoP—so facility leaders must inventory clinical and operational AI, keep human clinicians accountable for decisions, and document validation, monitoring, and safety review under Environment of Care and patient-safety expectations.

FDA QMSR AND AI/ML MEDICAL DEVICES

- QMSR applies to device manufacturers and importers responsible for quality systems—not to hospitals as manufacturers unless the facility actually designs or remanufactures devices. Where your organization deploys FDA-regulated AI/ML devices, your leverage points are procurement, implementation, maintenance, and surveillance.

WHAT MANUFACTURERS MUST SHOW UNDER QMSR

- For AI/ML SaMD and device software functions, manufacturer quality systems typically include:

FIELD QUESTION

When did FDA's QMSR take effect, and who must comply?

The Quality Management System Regulation (QMSR) amended 21 CFR Part 820 and became effective February 2, 2026, incorporating ISO 13485:2016 by reference. QMSR compliance obligations fall primarily on medical device manufacturers; hospitals using AI/ML devices must still maintain HTM oversight, vendor quality agreements, cybersecurity controls, and adverse-event reporting pathways aligned with FDA expectations.

From Healthcare Facility Hub - free, like everything on the site. The full article is at the link below.

Caution: codes, editions, and targets vary by facility and authority having jurisdiction (AHJ). Figures marked as common practice are facility targets, not code requirements. Confirm against your AHJ and the current code text before acting.